- Home
- BEAM vs CENTA Comparison
BEAM vs CENTA Comparison
Compare BEAM & CENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- CENTA
- Stock Information
- Founded
- BEAM 2017
- CENTA 1955
- Country
- BEAM United States
- CENTA United States
- Employees
- BEAM N/A
- CENTA N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- CENTA Consumer Specialties
- Sector
- BEAM Health Care
- CENTA Consumer Discretionary
- Exchange
- BEAM Nasdaq
- CENTA Nasdaq
- Market Cap
- BEAM 1.8B
- CENTA 2.1B
- IPO Year
- BEAM 2020
- CENTA 1993
- Fundamental
- Price
- BEAM $17.25
- CENTA $30.30
- Analyst Decision
- BEAM Strong Buy
- CENTA Buy
- Analyst Count
- BEAM 11
- CENTA 5
- Target Price
- BEAM $48.90
- CENTA $40.25
- AVG Volume (30 Days)
- BEAM 2.2M
- CENTA 340.9K
- Earning Date
- BEAM 05-06-2025
- CENTA 05-07-2025
- Dividend Yield
- BEAM N/A
- CENTA N/A
- EPS Growth
- BEAM N/A
- CENTA N/A
- EPS
- BEAM N/A
- CENTA 1.87
- Revenue
- BEAM $63,578,000.00
- CENTA $3,155,810,000.00
- Revenue This Year
- BEAM N/A
- CENTA $2.74
- Revenue Next Year
- BEAM $6.32
- CENTA $2.16
- P/E Ratio
- BEAM N/A
- CENTA $16.21
- Revenue Growth
- BEAM N/A
- CENTA N/A
- 52 Week Low
- BEAM $13.53
- CENTA $27.70
- 52 Week High
- BEAM $35.25
- CENTA $41.03
- Technical
- Relative Strength Index (RSI)
- BEAM 42.35
- CENTA 45.42
- Support Level
- BEAM $15.51
- CENTA $28.39
- Resistance Level
- BEAM $20.90
- CENTA $31.12
- Average True Range (ATR)
- BEAM 1.32
- CENTA 1.05
- MACD
- BEAM -0.02
- CENTA 0.01
- Stochastic Oscillator
- BEAM 32.28
- CENTA 63.66
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About CENTA Central Garden & Pet Company Nonvoting
Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.